Enliven Therapeutics Updates Positive Phase 1 Data For ELVN-001 In Chronic Myeloid Leukemia Patients
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Enliven Therapeutics Inc. (ELVN) announced updated, positive data from the Phase 1 clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia who have either failed available therapies, are intolerant to them, or are not candidates for these treatmen
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-722208811-b3d22c5e5c164942a1983f328bfe06be.jpg "How to Become a Retirement Super Saver")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-184827885-2--573b86c35f9b58723dbe24fa.jpg "<div>IPO vs. Staying Private: What's the Difference?</div>")